Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Core Insights - Teva Pharmaceutical Industries Ltd. is launching the acceleration phase of its "Pivot to Growth" strategy, aiming to evolve into a global biopharmaceutical leader and deliver sustained shareholder value through 2030 and beyond [1][3] Current Status - Teva has completed Phase 1 of its strategy, focusing on returning to growth and building a solid foundation, resulting in a more focused, innovative, and robust company [3] - The company has achieved 9 consecutive quarters of growth, with over $2.3 billion in revenue from its innovative portfolio in 2024 [6] Growth Engines - Teva targets to build a greater than $5 billion innovative medicines franchise by 2030, driven by products like AUSTEDO, AJOVY, and UZEDY, along with a robust pipeline of late-stage assets [4][5] - The innovative medicines franchise is expected to exceed $2.5 billion in sales by 2027 and over $3 billion by 2030 for AUSTEDO [7] Innovation Pipeline - Teva's late-stage pipeline includes several assets with blockbuster potential, such as duvakitug for inflammatory bowel disease, DARI for asthma, and emrusolmin for Multiple System Atrophy, with peak sales potential ranging from $1 billion to $5 billion [7][8] Generics and Biosimilars - Teva's generics, biosimilars, and OTC business remains a stable and cash-generating powerhouse, with a strong pipeline of complex generics and biosimilars [9] - The company plans to launch five new products by 2027 in its generics segment, with a focus on complex generics and biosimilars to offset revenue losses from gRevlimid [12] Financial Targets - Teva has reaffirmed its 2027 financial targets, including a 30% operating profit margin, free cash flow of over $2.7 billion in 2027, and a reduction of debt to 2x net leverage [10][12]